Jonathan J. Izygon

Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes.

A. Kaye, Ariel Winnick, E. Cornett, 2022, Health psychology research.

A subtype-specific neuropeptide FF receptor antagonist attenuates morphine and nicotine withdrawal syndrome in the rat

Caitlin A. Madison, E. Burstein, D. Malin, 2018, Neuroscience Letters.

Reversal of morphine tolerance by a compound with NPFF receptor subtype-selective actions

Caitlin A. Madison, E. Burstein, D. Malin, 2015, Neuroscience Letters.

Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

G. Varrassi, A. Kaye, Ariel Winnick, 2021, Neurology international.

Software for designing rigorous and replicable preclinical research: The Experimental Design Accelerator

Nicholas J. Kelling, Christopher P Ward, William R. Buras, 2019, Journal of neuroscience research.

Opicapone for the Treatment of Parkinson’s Disease "Off" Episodes: Pharmacology and Clinical Considerations

A. Kaye, Ariel Winnick, O. Viswanath, 2021, Clinical Drug Investigation.

Validation and scopolamine-reversal of latent learning in the water maze utilizing a revised direct platform placement procedure

D. Malin, Duyen M Nghiem, Krystal L. Schaar, 2015, Pharmacology Biochemistry and Behavior.